Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lorella, De Paoli"'
Autor:
Chiara Caprioli, Federico Lussana, Silvia Salmoiraghi, Roberta Cavagna, Ksenija Buklijas, Lara Elidi, Pamela Zanghi', Anna Michelato, Federica Delaini, Elena Oldani, Tamara Intermesoli, Anna Grassi, Giacomo Gianfaldoni, Francesco Mannelli, Dario Ferrero, Ernesta Audisio, Elisabetta Terruzzi, Lorella De Paoli, Chiara Cattaneo, Erika Borlenghi, Irene Cavattoni, Monica Tajana, Anna Maria Scattolin, Daniele Mattei, Paolo Corradini, Leonardo Campiotti, Fabio Ciceri, Massimo Bernardi, Elisabetta Todisco, Agostino Cortelezzi, Brunangelo Falini, Chiara Pavoni, Renato Bassan, Orietta Spinelli, Alessandro Rambaldi
Publikováno v:
Haematologica, Vol 106, Iss 10 (2020)
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these f
Externí odkaz:
https://doaj.org/article/86512554f32e4819856fc359461fbc77
Autor:
Anna Michelato, Fabio Ciceri, Dario Ferrero, Lorella De Paoli, Renato Bassan, Chiara Caprioli, Paolo Corradini, Silvia Salmoiraghi, Brunangelo Falini, Chiara Cattaneo, Giacomo Gianfaldoni, Agostino Cortelezzi, Federica Delaini, Alessandro Rambaldi, Francesco Mannelli, Leonardo Campiotti, Anna Maria Scattolin, Pamela Zanghì, Erika Borlenghi, Federico Lussana, Massimo Bernardi, Ksenija Buklijas, Daniele Mattei, Elena Oldani, Monica Tajana, Tamara Intermesoli, Roberta Cavagna, Anna De Grassi, Irene Cavattoni, Ernesta Audisio, Elisabetta Terruzzi, Orietta Spinelli, Lara Elidi, Elisabetta Todisco, Chiara Pavoni
Publikováno v:
Haematologica
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b29a752df00892435ddd6e3c36dc4ff
https://doi.org/10.3324/haematol.2020.252825
https://doi.org/10.3324/haematol.2020.252825
Autor:
Renato Bassan, Chiara Pavoni, Pamela Zanghì, Elisabetta Todisco, Nicola Stefano Fracchiolla, Anna Michelato, Leonardo Campiotti, Federico Lussana, Roberta Cavagna, Annamaria Scattolin, Giacomo Gianfaldoni, Chiara Caprioli, Erika Borlenghi, Fabio Ciceri, Ernesta Audisio, Alessandro Rambaldi, Lorella De Paoli, Tamara Intermesoli, Elisabetta Terruzzi, Orietta Spinelli, Ksenija Buklijas, Lara Elidi, Silvia Salmoiraghi, Paola Stefanoni, Paolo Corradini, Daniele Mattei, Irene Cavattoni, Monica Tajana, Elena Oldani
Publikováno v:
Cancers, Vol 12, Iss 2242, p 2242 (2020)
Cancers
Volume 12
Issue 8
Cancers
Volume 12
Issue 8
By way of a Next-Generation Sequencing NGS high throughput approach, we defined the mutational profile in a cohort of 221 normal karyotype acute myeloid leukemia (NK-AML) enrolled into a prospective randomized clinical trial, designed to evaluate an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b10bcb5b62308681575c3159b7c0502b
https://www.mdpi.com/2072-6694/12/8/2242
https://www.mdpi.com/2072-6694/12/8/2242
Autor:
Arianna Masciulli, Irene Cavattoni, Anna Maria Scattolin, Pamela Zanghì, Dario Ferrero, Lorella De Paoli, Chiara Cattaneo, Paolo Corradini, Elisabetta Terruzzi, Erika Borlenghi, Orietta Spinelli, Elisabetta Todisco, Brunangelo Falini, Agostino Cortelezzi, Chiara Pavoni, Sergio Cortelazzo, Giacomo Gianfaldoni, Alessandro Rambaldi, Filippo Marmont, Tamara Intermesoli, Daniele Mattei, Cristina Boschini, Elena Oldani, Renato Bassan, Fabio Ciceri, Massimo Bernardi, Ernesta Audisio, Enrico Pogliani, Leonardo Campiotti, Alberto Bosi
Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the early complete remission (CR) rate in acute myelogenous leukemia (AML) compared with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study enr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::584140c6f72a557f20b80d78efbd298b
https://europepmc.org/articles/PMC6457212/
https://europepmc.org/articles/PMC6457212/
Autor:
Elisabetta Todisco, Chiara Pavoni, Daniele Mattei, Federica Delaini, Alessandro Rambaldi, Agostino Cortelezzi, Monica Tajana, Paolo Corradini, Elena Oldani, Federico Lussana, Anna Maria Scattolin, Pamela Zanghì, Chiara Caprioli, Tamara Intermesoli, Brunangelo Falini, Giacomo Gianfaldoni, Elisabetta Terruzzi, Anna Michelato, Orietta Spinelli, Roberta Cavagna, Dario Ferrero, Lara Elidi, Silvia Salmoiraghi, Lorella De Paoli, Renato Bassan, Irene Cavattoni, Ernesta Audisio, Chiara Cattaneo, Fabio Ciceri, Ksenija Buklijas, Filippo Marmont, Leonardo Campiotti, Alberto Bosi, Massimo Bernardi, Erika Borlenghi, Sergio Cortelazzo
Publikováno v:
Blood. 134:1443-1443
Introduction Patients with secondary acute myeloid leukemia (sAML) after myelodysplastic (MDS) or myeloproliferative neoplasms (MPN) treated with chemotherapy show poorer outcomes compared with de novo AML; consequently, these cases should be allocat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0eb823d6a8b0669fbf40a38a357808c
https://doi.org/10.1182/blood-2019-124497
https://doi.org/10.1182/blood-2019-124497
Autor:
Daniele Mattei, Federica Delaini, Elisabetta Terruzzi, Elena Oldani, Paolo Corradini, Orietta Spinelli, Massimo Bernardi, Ernesta Audisio, Renato Bassan, Erika Borlenghi, Anna Maria Scattolin, Chiara Caprioli, Pamela Zanghì, Roberta Cavagna, Chiara Pavoni, Tamara Intermesoli, Chiara Cattaneo, Leonardo Campiotti, Agostino Cortelezzi, Alberto Bosi, Dario Ferrero, Anna Michelato, Silvia Salmoiraghi, Lorella De Paoli, Elisabetta Todisco, Fabio Ciceri, Brunangelo Falini, Federico Lussana, Sergio Cortelazzo, Giacomo Gianfaldoni, Alessandro Rambaldi, Monica Tajana, Irene Cavattoni, Ksenija Buklijas, Filippo Marmont
Publikováno v:
Blood. 132:434-434
Introduction In acute myeloid leukemia (AML) older age is independently associated with poor outcome, due to patient- and disease-related factors. Different genetic profiles characterize AML patients and their frequency varies according to age. Their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0564d166ebd9b9fd0a329cefeec7c0c5
https://doi.org/10.1182/blood-2018-99-113869
https://doi.org/10.1182/blood-2018-99-113869
Autor:
Alessandro, Pulsoni, Livio, Pagano, Roberto, Latagliata, Marco, Casini, Raffaella, Cerri, Monica, Crugnola, Lorella, De Paoli, Eros, Di Bona, Rosangela, Invernizzi, Filippo, Marmont, Maria Concetta, Petti, Gianmatteo, Rigolin, Francesca, Ronco, Antonio, Spadano, Maria Elena, Tosti, Giuseppe, Visani, Alfonso, Mele, Franco, Mandelli
Publikováno v:
Haematologica. 89(3)
The prognosis of elderly patients with acute myelogenous leukemia (AML) is usually dismal, while the true survival of older patients not included in clinical trials is not known. We retrospectively evaluated the impact on survival of an aggressive ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc7c427034464815dd0453a74089ad0f
https://pubmed.ncbi.nlm.nih.gov/15257963
https://pubmed.ncbi.nlm.nih.gov/15257963
Autor:
Daniela, Inverardi, Chiara, Bocchio, Lucia, Rossi, Laura, Mazzucco, Lorella, De Paoli, Piero, Borzini
Publikováno v:
Haematologica. 87(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ae9fe5d5b48285bcc28b2f827cb54090
https://pubmed.ncbi.nlm.nih.gov/12161372
https://pubmed.ncbi.nlm.nih.gov/12161372
Hematological Improvement in AML/RAEB Elderly Patients Treated with Valproic Acid and Low-Dose ARA-C
Autor:
Maria Teresa Corsetti, Massimo Pini, Valeria Primon, Anna Baraldi, G. Ciravegna, Alessandro Levis, Marco Musi, Bernardino Allione, Lorella De Paoli, Simona Gatto, Francesco Zallio, Alessandro Bellora, Daniela Pietrasanta, Flavia Salvi, Sonia Perticone, Anna Tonso
Publikováno v:
Blood. 112:2971-2971
Histone deacetilase inhibitors (HDCAi) have been shown to modulate gene expression with pro-differentiative effects. Valproic acid (VPA) has HDCAi activity and synergizes with Ara-C to differentiate AML blasts in vitro. VPA is orally applicable and h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::675f9925a7de744953291498bb3fcbd7
https://doi.org/10.1182/blood.v112.11.2971.2971
https://doi.org/10.1182/blood.v112.11.2971.2971